Effect	O
of	O
thymosin	O
on	O
glucocorticoid	B-protein
receptor	I-protein
activity	O
and	O
glucocorticoid	O
sensitivity	O
of	O
human	B-cell_type
thymocytes	I-cell_type
.	O

Incubation	O
with	O
thymosin	O
fraction	O
5	O
,	O
(	O
TMS	O
F5	O
at	O
300	O
micrograms/ml	O
)	O
a	O
partially	O
purified	O
thymic	O
factor	O
,	O
reduced	O
the	O
steroid	O
binding	O
activity	O
of	O
human	B-cell_type
infant	I-cell_type
thymocytes	I-cell_type
from	O
9.6	O
+/-	O
2.1	O
fmole/ml	O
to	O
5.0	O
+/-	O
2.0	O
fmole/ml	O
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
activity	O
in	O
normal	O
infant	O
thymocytes	O
was	O
found	O
to	O
be	O
2	O
,	O
146	O
+/-	O
726	O
(	O
s.d.	O
)	O
sites	O
per	O
cell	O
with	O
dissociation	O
constant	O
of	O
1.4	O
+/-	O
0.6	O
X	O
10	O
(	O
-8	O
)	O
M	O
.	O

TMS	O
F5	O
also	O
increased	O
the	O
resistance	O
of	O
human	O
thymocytes	O
to	O
the	O
cytolytic	O
effect	O
of	O
dexamethasone	O
(	O
2.5	O
X	O
10	O
(	O
-8	O
)	O
M	O
)	O
to	O
168.6	O
+/-	O
30.2	O
%	O
of	O
control	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

In	O
animals	O
,	O
medullary	B-cell_type
and	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
more	O
resistant	O
to	O
glucocorticoids	O
than	O
immature	B-cell_type
thymic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
results	O
show	O
that	O
thymosin	O
can	O
induce	O
changes	O
consistent	O
with	O
differentiation	O
in	O
human	B-cell_type
thymocytes	I-cell_type
.	O

These	O
in	O
vitro	O
results	O
are	O
consistent	O
with	O
a	O
physiological	O
role	O
of	O
thymosin	O
in	O
intrathymic	O
T	O
cell	O
maturation	O
in	O
man	O
.	O

Incubation	O
of	O
a	O
human	B-cell_line
malignant	I-cell_line
thymus	I-cell_line
derived	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
MOLT	B-cell_line
3	I-cell_line
)	O
with	O
TMS	O
F5	O
also	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
number	O
of	O
steroid	O
binding	O
sites	O
to	O
44.2	O
+/-	O
15.3	O
%	O
of	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
but	O
TMS	O
F5	O
did	O
not	O
significantly	O
reduce	O
the	O
glucocorticoid	O
sensitivity	O
of	O
MOLT	B-cell_line
3	I-cell_line
cells	I-cell_line
.	O

Clin	NULL
.	NULL

exp	NULL
.	NULL

Immunol	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
55	NULL
,	NULL
273-280	NULL
.	NULL

Effect	NULL
of	NULL
thymosin	NULL
on	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
and	NULL
glucocorticoid	NULL
sensitivity	NULL
of	NULL
human	NULL
thymocytes	NULL
D.D.F	NULL
.	NULL

MA	NULL
,	NULL
A.	NULL
H.	NULL
HO	NULL
&	NULL
A.	NULL
V.	NULL
HOFFBRAND	NULL
Department	NULL
of	NULL
Haematology	NULL
,	NULL
Royal	NULL
Free	NULL
Hospital	NULL
and	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Hampstead	NULL
,	NULL
London	NULL
,	NULL
UK	NULL
(	NULL
Accepted	NULL
for	NULL
publication	NULL
10	NULL
October	NULL
1983	NULL
)	NULL
SUMMARY	NULL
Incubation	NULL
with	NULL
thymosin	NULL
fraction	NULL
5	NULL
,	NULL
(	NULL
TMS	NULL
F5	NULL
at	NULL
300	NULL
ug/ml	NULL
)	NULL
a	NULL
partially	NULL
purified	NULL
thymic	NULL
factor	NULL
,	NULL
reduced	NULL
the	NULL
steroid	NULL
binding	NULL
activity	NULL
of	NULL
human	NULL
infant	NULL
thymocytes	NULL
from	NULL
9:6	NULL
+21	NULL
fmole/ml	NULL
to	NULL
5:0+2-0	NULL
fmole/ml	NULL
.	NULL

The	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
in	NULL
normal	NULL
infant	NULL
thymocytes	NULL
was	NULL
found	NULL
to	NULL
be	NULL
2,146	NULL
+726	NULL
(	NULL
s.d	NULL
.	NULL
)	NULL

sites	NULL
per	NULL
cell	NULL
with	NULL
dissociation	NULL
constant	NULL
of	NULL
1-4+0-6x	NULL
10-	NULL
'm	NULL
.	NULL

TMS	NULL
F5	NULL
also	NULL
increased	NULL
the	NULL
resistance	NULL
of	NULL
human	NULL
thymocytes	NULL
to	NULL
the	NULL
cytolytic	NULL
effect	NULL
of	NULL
dexamethasone	NULL
(	NULL
2:5	NULL
x	NULL
10-Â®m	NULL
)	NULL
to	NULL
168:6	NULL
+	NULL
30-2	NULL
%	NULL
of	NULL
control	NULL
(	NULL
P	NULL
<	NULL
0-01	NULL
)	NULL
.	NULL

In	NULL
animals	NULL
,	NULL
medullary	NULL
and	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
are	NULL
more	NULL
resistant	NULL
to	NULL
glucocorticoids	NULL
than	NULL
immature	NULL
thymic	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
thymosin	NULL
can	NULL
induce	NULL
changes	NULL
consistent	NULL
with	NULL
differentiation	NULL
in	NULL
human	NULL
thymocytes	NULL
.	NULL

These	NULL
in	NULL
vitro	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
physiological	NULL
role	NULL
of	NULL
thymosin	NULL
in	NULL
intrathymic	NULL
T	NULL
cell	NULL
maturation	NULL
in	NULL
man	NULL
.	NULL

Incubation	NULL
of	NULL
a	NULL
human	NULL
malignant	NULL
thymus	NULL
derived	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
MOLT	NULL
3	NULL
)	NULL
with	NULL
TMS	NULL
F5	NULL
also	NULL
resulted	NULL
in	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
the	NULL
number	NULL
of	NULL
steroid	NULL
binding	NULL
sites	NULL
to	NULL
442+	NULL
15-3	NULL
%	NULL
of	NULL
control	NULL
(	NULL
P	NULL
<	NULL
0-05	NULL
)	NULL
,	NULL
but	NULL
TMS	NULL
F5	NULL
did	NULL
not	NULL
significantly	NULL
reduce	NULL
the	NULL
glucocorticoid	NULL
sensitivity	NULL
of	NULL
MOLT	NULL
3	NULL
cells	NULL
.	NULL

Keywords	NULL
human	NULL
thymocytes	NULL
glucocorticoid	NULL
receptors	NULL
thymosin	NULL
INTRODUCTION	NULL
Studies	NULL
in	NULL
animals	NULL
have	NULL
shown	NULL
that	NULL
two	NULL
major	NULL
classes	NULL
of	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
distinguished	NULL
in	NULL
the	NULL
thymus	NULL
;	NULL
immunoincompetent	NULL
,	NULL
glucocorticoid	NULL
sensitive	NULL
cortical	NULL
thymocytes	NULL
and	NULL
immunocompetent	NULL
,	NULL
glucocorticoid	NULL
resistant	NULL
medullary	NULL
thymocytes	NULL
.	NULL

Thymic	NULL
T	NULL
cell	NULL
precursors	NULL
are	NULL
also	NULL
thought	NULL
to	NULL
be	NULL
resistant	NULL
to	NULL
glucocorticoids	NULL
(	NULL
Claman	NULL
,	NULL
1972	NULL
)	NULL
.	NULL

The	NULL
action	NULL
of	NULL
glucocorticoids	NULL
is	NULL
a	NULL
multiple	NULL
step	NULL
process	NULL
which	NULL
involves	NULL
specific	NULL
intracellular	NULL
receptors	NULL
(	NULL
Higgins	NULL
&	NULL
Gehring	NULL
,	NULL
1978	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
number	NULL
of	NULL
specific	NULL
glucocorticoid	NULL
receptor	NULL
sites	NULL
(	NULL
Baxter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
Rosenau	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1972	NULL
)	NULL
.	NULL

However	NULL
,	NULL
studies	NULL
on	NULL
HeLa	NULL
cells	NULL
(	NULL
Cidlowski	NULL
&	NULL
Michaels	NULL
,	NULL
1977	NULL
)	NULL
and	NULL
mitogen	NULL
stimulated	NULL
human	NULL
lymphocytes	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
receptor	NULL
number	NULL
correlates	NULL
with	NULL
proliferative	NULL
stage	NULL
and	NULL
may	NULL
not	NULL
determine	NULL
glucocorticoid	NULL
sensitivity	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
cellular	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
additional	NULL
factors	NULL
.	NULL

Several	NULL
thymic	NULL
factors	NULL
have	NULL
been	NULL
isolated	NULL
from	NULL
thymus	NULL
and	NULL
serum	NULL
(	NULL
reviewed	NULL
by	NULL
Goldstein	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

Experimental	NULL
observations	NULL
in	NULL
animals	NULL
support	NULL
the	NULL
role	NULL
of	NULL
these	NULL
factors	NULL
in	NULL
normal	NULL
T	NULL
cell	NULL
differentiation	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
thymosin	NULL
has	NULL
been	NULL
found	NULL
to	NULL
induce	NULL
E	NULL
rosette	NULL
receptors	NULL
in	NULL
some	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
cells	NULL
(	NULL
Horowitz	NULL
&	NULL
Goldstein	NULL
,	NULL
1978	NULL
)	NULL
,	NULL
and	NULL
it	NULL
has	NULL
also	NULL
been	NULL
found	NULL
to	NULL
enhance	NULL
the	NULL
function	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
Horowitz	NULL
&	NULL
Goldstein	NULL
,	NULL
1978	NULL
;	NULL
Goldstein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

Osheroff	NULL
(	NULL
1981	NULL
)	NULL
and	NULL
Goldstein	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
demonstrated	NULL
that	NULL
thymosin	NULL
peptides	NULL
alter	NULL
steroid	NULL
responsiveness	NULL
and	NULL
Correspondence	NULL
:	NULL
Dr	NULL
D.D.F	NULL
.	NULL

Ma	NULL
,	NULL
Department	NULL
of	NULL
Haematology	NULL
,	NULL
St	NULL
Vincent	NULL
's	NULL
Hospital	NULL
,	NULL
Sydney	NULL
,	NULL
New	NULL
South	NULL
Wales	NULL
2010	NULL
,	NULL
Australia	NULL
.	NULL

273	NULL
274	NULL
D.	NULL
D.	NULL
F.	NULL
Ma	NULL
,	NULL
A.	NULL
H.	NULL
Ho	NULL
&	NULL
A.	NULL
V.	NULL
Hoffbrand	NULL
steroid	NULL
binding	NULL
of	NULL
murine	NULL
thymocytes	NULL
.	NULL

However	NULL
,	NULL
lymphocytes	NULL
of	NULL
some	NULL
species	NULL
,	NULL
such	NULL
as	NULL
man	NULL
,	NULL
are	NULL
relatively	NULL
resistant	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
and	NULL
may	NULL
respond	NULL
differently	NULL
to	NULL
thymosin	NULL
(	NULL
Harris	NULL
&	NULL
Baxter	NULL
,	NULL
1979	NULL
)	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
examine	NULL
the	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
the	NULL
physiological	NULL
hormone	NULL
thymosin	NULL
fraction	NULL
5	NULL
(	NULL
TMS	NULL
F5	NULL
)	NULL
and	NULL
other	NULL
T	NULL
cell	NULL
inducing	NULL
agents	NULL
on	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
status	NULL
and	NULL
steroid	NULL
sensitivity	NULL
of	NULL
normal	NULL
human	NULL
thymocytes	NULL
and	NULL
of	NULL
a	NULL
human	NULL
thymus	NULL
derived	NULL
leukaemia	NULL
cell	NULL
line	NULL
(	NULL
MOLT	NULL
3	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

Human	NULL
thymocytes	NULL
were	NULL
obtained	NULL
by	NULL
teasing	NULL
thymic	NULL
specimens	NULL
obtained	NULL
from	NULL
children	NULL
(	NULL
age	NULL
range	NULL
from	NULL
3	NULL
months	NULL
to	NULL
3	NULL
years	NULL
old	NULL
)	NULL
undergoing	NULL
open	NULL
cardiac	NULL
surgery	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
suspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
L-glutamine	NULL
and	NULL
antibiotics	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
checked	NULL
by	NULL
the	NULL
trypan	NULL
blue	NULL
(	NULL
0-2	NULL
%	NULL
)	NULL
exclusion	NULL
test	NULL
and	NULL
was	NULL
always	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
.	NULL

Cell	NULL
counts	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
an	NULL
electronic	NULL
cell	NULL
counter	NULL
(	NULL
Coulter	NULL
S	NULL
,	NULL
Coulter	NULL
Electronics	NULL
,	NULL
UK	NULL
)	NULL
or	NULL
manually	NULL
with	NULL
an	NULL
improved	NULL
Neubauer	NULL
Chamber	NULL
.	NULL

Human	NULL
malignant	NULL
lymphoid	NULL
cell	NULL
lines	NULL
,	NULL
MOLT	NULL
3	NULL
(	NULL
derived	NULL
from	NULL
a	NULL
thymic	NULL
acute	NULL
lymphoblastic	NULL
leukaemia	NULL
case	NULL
)	NULL
and	NULL
RAJI	NULL
(	NULL
from	NULL
a	NULL
B	NULL
cell	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
)	NULL
were	NULL
kindly	NULL
donated	NULL
by	NULL
Dr	NULL
M.F	NULL
.	NULL

Greaves	NULL
,	NULL
Department	NULL
of	NULL
Membrane	NULL
Immunology	NULL
,	NULL
Imperial	NULL
Cancer	NULL
Research	NULL
Fund	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
in	NULL
logarithmic	NULL
growth	NULL
and	NULL
suspended	NULL
in	NULL
fresh	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
prior	NULL
to	NULL
use	NULL
.	NULL

TMS	NULL
F5	NULL
was	NULL
supplied	NULL
by	NULL
Dr	NULL
W.E	NULL
.	NULL

Scott	NULL
(	NULL
Hoffman	NULL
La	NULL
Roche	NULL
,	NULL
New	NULL
Jersey	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Thymopoietin	NULL
pentapeptide	NULL
(	NULL
TP5	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Universal	NULL
Biological	NULL
Ltd.	NULL
(	NULL
Cambridge	NULL
,	NULL
UK	NULL
)	NULL
and	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
i.e	NULL
.	NULL

T	NULL
cell	NULL
growth	NULL
factor	NULL
which	NULL
induces	NULL
proliferation	NULL
of	NULL
antigen	NULL
pre-activated	NULL
T	NULL
cells	NULL
)	NULL
was	NULL
from	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
Ltd.	NULL
,	NULL
UK	NULL
.	NULL

12-O-tetradecanoylphorbol	NULL
L3-acetate	NULL
(	NULL
TPA	NULL
)	NULL
,	NULL
bovine	NULL
albumin	NULL
and	NULL
dexamethasone	NULL
(	NULL
9-x-fluoro-l6x-methyl	NULL
prednisone	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
Ltd.	NULL
,	NULL
UK	NULL
.	NULL

Culture	NULL
medium	NULL
RPMI	NULL
1640	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
and	NULL
culture	NULL
supplements	NULL
(	NULL
L-glutamine	NULL
and	NULL
antibiotics	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
GiBco	NULL
Europe	NULL
Ltd.	NULL
,	NULL
UK	NULL
.	NULL

Hepes	NULL
,	NULL
tissue	NULL
culture	NULL
plates	NULL
and	NULL
flasks	NULL
were	NULL
purchased	NULL
from	NULL
Flow	NULL
Laboratories	NULL
,	NULL
UK..	NULL
(	NULL
specific	NULL
activity	NULL
40-47Ci/mmol	NULL
)	NULL
and	NULL
methyl-H-thy-midine	NULL
(	NULL
specific	NULL
activity	NULL
5	NULL
Ci/mmol	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Amersham	NULL
International	NULL
,	NULL
UK	NULL
.	NULL

In	NULL
vitro	NULL
incubation	NULL
experiments	NULL
.	NULL

Human	NULL
thymocytes	NULL
(	NULL
5-6	NULL
x	NULL
10Â°/ml	NULL
)	NULL
in	NULL
RPMI	NULL
medium	NULL
with	NULL
2	NULL
%	NULL
FCS	NULL
were	NULL
incubated	NULL
with	NULL
or	NULL
without	NULL
TMS	NULL
F5	NULL
or	NULL
other	NULL
substances	NULL
for	NULL
18-20	NULL
h	NULL
at	NULL
37Â°C	NULL
in	NULL
humidified	NULL
air	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
suspended	NULL
in	NULL
RPMI	NULL
medium	NULL
with	NULL
Hepes	NULL
(	NULL
5mm	NULL
)	NULL
since	NULL
serum	NULL
contains	NULL
specific	NULL
proteins	NULL
,	NULL
e.g	NULL
.	NULL

corticosteroid	NULL
binding	NULL
globulin	NULL
which	NULL
may	NULL
interfere	NULL
with	NULL
the	NULL
glucocorticoid	NULL
assays	NULL
.	NULL

MOLT	NULL
3	NULL
cells	NULL
were	NULL
incubated	NULL
under	NULL
similar	NULL
conditions	NULL
at	NULL
a	NULL
cell	NULL
concentration	NULL
of	NULL
1-2	NULL
x	NULL
10Â®/ml	NULL
in	NULL
humidified	NULL
air	NULL
with	NULL
5	NULL
%	NULL
,	NULL
CO	NULL
;	NULL
at	NULL
37Â°C	NULL
.	NULL

After	NULL
4	NULL
days	NULL
of	NULL
incubation	NULL
with	NULL
TMS	NULL
F5	NULL
or	NULL
TPA	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
suspended	NULL
in	NULL
medium	NULL
without	NULL
serum	NULL
as	NULL
above	NULL
,	NULL
before	NULL
testing	NULL
for	NULL
steroid	NULL
receptors	NULL
and	NULL
sensitivity	NULL
.	NULL

The	NULL
incubation	NULL
time	NULL
was	NULL
chosen	NULL
because	NULL
previous	NULL
experiments	NULL
demonstrated	NULL
that	NULL
changes	NULL
in	NULL
differentiation	NULL
markers	NULL
by	NULL
thymosin	NULL
and	NULL
TPA	NULL
were	NULL
most	NULL
marked	NULL
by	NULL
4	NULL
days	NULL
(	NULL
Ho	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1983a	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
viability	NULL
of	NULL
treated	NULL
samples	NULL
did	NULL
not	NULL
differ	NULL
from	NULL
that	NULL
of	NULL
the	NULL
control	NULL
cells	NULL
.	NULL

Determination	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
based	NULL
on	NULL
the	NULL
method	NULL
of	NULL
Baxter	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
.	NULL

Samples	NULL
at	NULL
4-6	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
were	NULL
tested	NULL
in	NULL
triplicate	NULL
.	NULL

Aliquots	NULL
of	NULL
1	NULL
ml	NULL
were	NULL
incubated	NULL
with	NULL
Â°H-dexamethasone	NULL
at	NULL
concentrations	NULL
from	NULL
5	NULL
x	NULL
10Â®m	NULL
to	NULL
1	NULL
x	NULL
10-Â°m	NULL
for	NULL
45	NULL
min	NULL
at	NULL
37Â°C	NULL
in	NULL
siliconized	NULL
glass	NULL
tubes	NULL
(	NULL
12	NULL
x	NULL
75	NULL
mm	NULL
,	NULL
Scientific	NULL
Products	NULL
,	NULL
Illinois	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Non-specific	NULL
binding	NULL
was	NULL
measured	NULL
from	NULL
parallel	NULL
triplicate	NULL
sets	NULL
by	NULL
adding	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
dexamethasone	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
cold	NULL
PBS	NULL
and	NULL
washed	NULL
twice	NULL
at	NULL
20Â°C	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
suspended	NULL
in	NULL
1	NULL
ml	NULL
cold	NULL
ethanol	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
scintillation	NULL
vial	NULL
with	NULL
10	NULL
ml	NULL
of	NULL
scintillation	NULL
fluid	NULL
(	NULL
Packard	NULL
Instrument	NULL
Co.	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Radioactivity	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
#	NULL
counter	NULL
(	NULL
LKB	NULL
,	NULL
1210	NULL
Ultrobeta	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Specific	NULL
dexamethasone	NULL
binding	NULL
was	NULL
taken	NULL
as	NULL
total	NULL
binding	NULL
minus	NULL
non-specific	NULL
binding	NULL
.	NULL

The	NULL
number	NULL
of	NULL
receptor	NULL
sites	NULL
were	NULL
estimated	NULL
by	NULL
Scatchard	NULL
analysis	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
due	NULL
to	NULL
limited	NULL
cell	NULL
numbers	NULL
,	NULL
comparisons	NULL
were	NULL
made	NULL
by	NULL
determining	NULL
receptor	NULL
binding	NULL
at	NULL
a	NULL
single	NULL
concentration	NULL
Thymosin	NULL
effect	NULL
on	NULL
human	NULL
thymocytes	NULL
275	NULL
(	NULL
near	NULL
maximum	NULL
)	NULL
of	NULL
'	NULL
H-dexamethasone	NULL
(	NULL
2:5	NULL
x	NULL
10-Â®m	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
always	NULL
greater	NULL
than	NULL
85	NULL
%	NULL
throughout	NULL
the	NULL
experiment	NULL
.	NULL

Assay	NULL
for	NULL
glucocorticoid	NULL
sensitivity	NULL
of	NULL
thymosin	NULL
treated	NULL
and	NULL
untreated	NULL
cells	NULL
.	NULL

After	NULL
pre-incubation	NULL
at	NULL
37Â°C	NULL
alone	NULL
or	NULL
with	NULL
TMS	NULL
F5	NULL
,	NULL
or	NULL
other	NULL
compounds	NULL
in	NULL
humidified	NULL
air	NULL
with	NULL
5	NULL
%	NULL
,	NULL
CO	NULL
;	NULL
,	NULL
cells	NULL
(	NULL
thymocytes	NULL
or	NULL
leukaemic	NULL
cells	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
fresh	NULL
medium	NULL
with	NULL
or	NULL
without	NULL
addition	NULL
of	NULL
25x	NULL
10-	NULL
%	NULL
m	NULL
dexamethasone	NULL
.	NULL

After	NULL
6-8	NULL
h	NULL
,	NULL
aliquots	NULL
were	NULL
removed	NULL
for	NULL
'	NULL
H-thymidine	NULL
uptake	NULL
estimation	NULL
and	NULL
after	NULL
20	NULL
h	NULL
cells	NULL
were	NULL
checked	NULL
for	NULL
viability	NULL
using	NULL
trypan	NULL
blue	NULL
.	NULL

(	NULL
a	NULL
)	NULL
'	NULL
H-thymidine	NULL
uptake	NULL
Cells	NULL
at	NULL
1x	NULL
10	NULL
%	NULL
/ml	NULL
were	NULL
incubated	NULL
with	NULL
'	NULL
H-thymidine	NULL
(	NULL
1	NULL
wCi/m	NULL
!	NULL

l	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37Â°C	NULL
.	NULL

Tests	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
with	NULL
cold	NULL
PBS	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
.	NULL

Acid	NULL
insoluble	NULL
nucleic	NULL
acid	NULL
extract	NULL
was	NULL
precipitated	NULL
by	NULL
0-5	NULL
m	NULL
perchloroacetic	NULL
acid	NULL
and	NULL
processed	NULL
for	NULL
determination	NULL
of	NULL
radioactivity	NULL
.	NULL

'Relative	NULL
'	NULL
*H-thymidine	NULL
uptake/l	NULL
x	NULL
10Â°	NULL
cells	NULL
is	NULL
expressed	NULL
as	NULL
mean	NULL
of	NULL
ct/min	NULL
incorporated	NULL
after	NULL
dexamethasone	NULL
treatment	NULL
mean	NULL
of	NULL
ct/min	NULL
incorporated	NULL
without	NULL
dexamethasone	NULL
treatment	NULL
(	NULL
b	NULL
)	NULL
Trypan	NULL
blue	NULL
dye	NULL
(	NULL
0-2	NULL
%	NULL
,	NULL
)	NULL
exclusion	NULL
test	NULL
This	NULL
was	NULL
used	NULL
to	NULL
assess	NULL
cell	NULL
viability	NULL
.	NULL

Counting	NULL
was	NULL
performed	NULL
in	NULL
triplicate	NULL
using	NULL
a	NULL
modified	NULL
Neubauer	NULL
chamber	NULL
.	NULL

'Relative	NULL
'	NULL
cell	NULL
viability	NULL
of	NULL
.a	NULL
sample	NULL
is	NULL
defined	NULL
as	NULL
mean	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
after	NULL
dexamethasone	NULL
treatment	NULL
mean	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
without	NULL
dexamethasone	NULL
treatment	NULL
All	NULL
results	NULL
were	NULL
expressed	NULL
as	NULL
mean	NULL
+s.d	NULL
.	NULL

unless	NULL
stated	NULL
otherwise	NULL
.	NULL

Tests	NULL
for	NULL
significance	NULL
were	NULL
performed	NULL
using	NULL
Student	NULL
's	NULL
paired	NULL
f-test	NULL
.	NULL

RESULTS	NULL
Normal	NULL
thymocytes	NULL
Effect	NULL
of	NULL
TMS	NULL
F5	NULL
on	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

In	NULL
six	NULL
experiments	NULL
using	NULL
[	NULL
PH	NULL
]	NULL
-dexamethasone	NULL
,	NULL
normal	NULL
thymocytes	NULL
were	NULL
found	NULL
to	NULL
have	NULL
2,146+726	NULL
s.d	NULL
.	NULL

specific	NULL
binding	NULL
sites	NULL
per	NULL
cell	NULL
and	NULL
a	NULL
dissociation	NULL
constant	NULL
(	NULL
kd	NULL
)	NULL
of	NULL
1-4+0-6	NULL
x	NULL
10-Â®m	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
two	NULL
experiments	NULL
,	NULL
incubation	NULL
of	NULL
thymocytes	NULL
with	NULL
TMS	NULL
F5	NULL
(	NULL
150	NULL
ug/ml	NULL
)	NULL
,	NULL
lowered	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
to	NULL
1,132	NULL
and	NULL
2,015	NULL
per	NULL
Table	NULL
1	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
in	NULL
normal	NULL
human	NULL
thymocytes	NULL
Correlation	NULL
Ka	NULL
Receptor	NULL
binding	NULL
Receptor	NULL
sites	NULL
coefficient*	NULL
(	NULL
x	NULL
10~Â®m	NULL
)	NULL
(	NULL
fmole/ml	NULL
)	NULL
per	NULL
cell	NULL
1	NULL
0-92	NULL
14	NULL
15-4	NULL
1,855	NULL
2	NULL
0-83	NULL
23	NULL
14-2	NULL
1,710	NULL
3	NULL
0-88	NULL
0-6	NULL
15-2	NULL
1,831	NULL
4	NULL
0-90	NULL
1-3	NULL
127	NULL
1,530	NULL
5	NULL
0-96	NULL
1+7	NULL
20-5	NULL
2,469	NULL
6	NULL
0-83	NULL
1-0	NULL
28-9	NULL
3,480	NULL
Mean	NULL
14	NULL
17-8	NULL
2,146	NULL
+s.d	NULL
.	NULL

+06	NULL
+	NULL
60	NULL
+	NULL
726	NULL
*	NULL
Correlation	NULL
coefficient	NULL
,	NULL
determined	NULL
from	NULL
Scatchard	NULL
analysis	NULL
of	NULL
the	NULL
data	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

276	NULL
D.	NULL
D.	NULL
F.	NULL
Ma	NULL
,	NULL
A.	NULL
H.	NULL
Ho	NULL
&	NULL
A.	NULL
V.	NULL
Hoffbrand	NULL
Specifically	NULL
bound	NULL
H	NULL
-dexamethasone	NULL
(	NULL
fmote/ml	NULL
)	NULL
0	NULL
5	NULL
10	NULL
15	NULL
|	NULL
|	NULL
\	NULL
|	NULL
Bound	NULL
(	NULL
fmole/ml	NULL
)	NULL
o	NULL
O6	NULL
25	NULL
25	NULL
3-75	NULL
Dexamethasone	NULL
concentration	NULL
(	NULL
x	NULL
10~Â®	NULL
m	NULL
)	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Specific	NULL
*H-dexamethasone	NULL
binding	NULL
to	NULL
human	NULL
thymocytes	NULL
[	NULL
control	NULL
,	NULL
0	NULL
;	NULL
TMS	NULL
F5	NULL
(	NULL
1	NULL
50	NULL
ug/ml	NULL
)	NULL
treated	NULL
cells	NULL
,	NULL
@	NULL
]	NULL
.	NULL

The	NULL
Scatchard	NULL
analysis	NULL
is	NULL
shown	NULL
in	NULL
the	NULL
inset	NULL
.	NULL

r	NULL
;	NULL
and	NULL
r	NULL
;	NULL
are	NULL
the	NULL
correlation	NULL
coefficients	NULL
of	NULL
the	NULL
Scatchard	NULL
analysis	NULL
of	NULL
the	NULL
control	NULL
and	NULL
of	NULL
thymosin	NULL
treated	NULL
cell	NULL
respectively	NULL
.	NULL

cell	NULL
compared	NULL
to	NULL
control	NULL
levels	NULL
of	NULL
1,831	NULL
and	NULL
3,480	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
results	NULL
of	NULL
one	NULL
experiment	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
treatment	NULL
with	NULL
various	NULL
compounds	NULL
on	NULL
the	NULL
steroid	NULL
receptors	NULL
of	NULL
thymocytes	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

TMS	NULL
F5	NULL
at	NULL
concentrations	NULL
of	NULL
150	NULL
and	NULL
300	NULL
ug/ml	NULL
reduced	NULL
the	NULL
specific	NULL
steroid	NULL
binding	NULL
of	NULL
thymocytes	NULL
to	NULL
49:2	NULL
+	NULL
126	NULL
%	NULL
,	NULL
and	NULL
46-3	NULL
+22-0	NULL
%	NULL
of	NULL
the	NULL
control	NULL
,	NULL
respectively	NULL
.	NULL

TMS	NULL
F5	NULL
at	NULL
50	NULL
and	NULL
25	NULL
ug/ml	NULL
,	NULL
TPA	NULL
,	NULL
TP5	NULL
,	NULL
IL-2	NULL
and	NULL
albumin	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
steroid	NULL
receptor	NULL
status	NULL
significantly	NULL
.	NULL
'	NULL

H-thymidine	NULL
uptake	NULL
and	NULL
cell	NULL
viability	NULL
of	NULL
thymocytes	NULL
incubated	NULL
with	NULL
thymosin	NULL
were	NULL
similar	NULL
to	NULL
the	NULL
control	NULL
and	NULL
other	NULL
treated	NULL
groups	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
TMS	NULL
F5	NULL
on	NULL
glucocorticoid	NULL
sensitivity	NULL
.	NULL

Infant	NULL
thymocytes	NULL
were	NULL
found	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
dexamethasone	NULL
(	NULL
2:5	NULL
x	NULL
10-Â®m	NULL
)	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
marked	NULL
reduction	NULL
in	NULL
cell	NULL
Table	NULL
2	NULL
.	NULL

Specific	NULL
PH	NULL
]	NULL
-dexamethasone	NULL
binding	NULL
to	NULL
thymocytes	NULL
after	NULL
incubation	NULL
with	NULL
various	NULL
compounds	NULL
TMS	NULL
-	NULL
TMS	NULL
-	NULL
TMS	NULL
TMS	NULL
IL-2	NULL
-	NULL
Alb	NULL
TPA	NULL
TPs	NULL
300	NULL
150	NULL
50	NULL
250	NULL
(	NULL
10	NULL
%	NULL
)	NULL
100	NULL
(	NULL
10	NULL
1	NULL
Control	NULL
(	NULL
ug/ml	NULL
)	NULL
(	NULL
ug/ml	NULL
)	NULL
(	NULL
ug/ml	NULL
)	NULL
(	NULL
ug/ml	NULL
!	NULL
)	NULL

(	NULL
ug/ml	NULL
!	NULL
)	NULL

(	NULL
ng/ml	NULL
)	NULL
(	NULL
pg/ml	NULL
)	NULL
No	NULL
.	NULL

of	NULL
samples	NULL
7	NULL
4	NULL
3	NULL
3	NULL
3	NULL
3	NULL
3	NULL
3	NULL
3	NULL
Specific	NULL
binding	NULL
_	NULL
9-6	NULL
l	NULL
53+	NULL
5-8	NULL
62	NULL
8-3	NULL
7-5	NULL
9-3	NULL
7-4	NULL
(	NULL
fmole/m	NULL
!	NULL

1	NULL
)	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
241	NULL
20	NULL
241	NULL
1-0	NULL
1-0	NULL
0-4	NULL
1-6	NULL
36	NULL
1-0	NULL
%	NULL
,	NULL
of	NULL
control	NULL
100	NULL
__	NULL
463*	NULL
_	NULL
492+	NULL
_	NULL
626	NULL
799	NULL
973	NULL
I10lL3	NULL
1258	NULL
-	NULL
979	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
just	NULL
+	NULL
just	NULL
+	NULL
+	NULL
22	NULL
126	NULL
19	NULL
178	NULL
_	NULL
237	NULL
-	NULL
228	NULL
327	NULL
66	NULL
Specific	NULL
dexamethasone	NULL
binding	NULL
was	NULL
estimated	NULL
at	NULL
25	NULL
%	NULL
107m	NULL
of	NULL
*H-dexamethasone	NULL
(	NULL
mean	NULL
+	NULL
s.d	NULL
.	NULL
)	NULL

.	NULL

TMS=TMS	NULL
F5	NULL
;	NULL
IL-2=interleukin-2	NULL
(	NULL
1:10	NULL
dilution	NULL
)	NULL
;	NULL
ALB=albumin	NULL
;	NULL
TPA=tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
;	NULL
TPS=thymopoietin	NULL
pentapeptide	NULL
.	NULL

*	NULL
P	NULL
<	NULL
0-01	NULL
;	NULL
t	NULL
P	NULL
<	NULL
0-02	NULL
.	NULL

Thymosin	NULL
effect	NULL
on	NULL
human	NULL
thymocytes	NULL
277	NULL
Table	NULL
3	NULL
.	NULL

Effect	NULL
of	NULL
incubation	NULL
with	NULL
TMS	NULL
F5	NULL
and	NULL
IL-2	NULL
on	NULL
dexamethasone	NULL
sensitivity	NULL
of	NULL
thymocytes	NULL
(	NULL
mean	NULL
+s.d	NULL
.	NULL
)	NULL

TMS	NULL
TMS	NULL
_	NULL
TMS	NULL
300	NULL
150	NULL
50	NULL
Control	NULL
,	NULL
.	NULL

(	NULL
ug/ml	NULL
!	NULL
)	NULL

(	NULL
ug/ml	NULL
)	NULL
(	NULL
ug/ml	NULL
)	NULL
_	NULL
IL-2	NULL
No	NULL
.	NULL

of	NULL
samples	NULL
5	NULL
5	NULL
2	NULL
3	NULL
2	NULL
Viable	NULL
cells	NULL
06	NULL
0-9	NULL
1-2	NULL
0-8	NULL
0-9	NULL
(	NULL
x	NULL
105/ml	NULL
)	NULL
with	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
dexamethasone	NULL
0-3	NULL
0-5	NULL
1-0	NULL
0-4	NULL
0-55	NULL
Viable	NULL
cells	NULL
1-7	NULL
1-6	NULL
1-8	NULL
23	NULL
1-6	NULL
(	NULL
x	NULL
105/ml	NULL
)	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
without	NULL
0-5	NULL
0-4	NULL
0-5	NULL
0-65	NULL
06	NULL
dexamethasone	NULL
*Relative	NULL
'	NULL
cell	NULL
33-8	NULL
55-6*	NULL
60-0	NULL
38-3	NULL
50-5	NULL
viability	NULL
(	NULL
%	NULL
)	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
97	NULL
-	NULL
400	NULL
0	NULL
382000	NULL
134	NULL
Viability	NULL
compared	NULL
168:6*	NULL
_	NULL
1627	NULL
1057	NULL
1252	NULL
to	NULL
control	NULL
+	NULL
+	NULL
+	NULL
+	NULL
302	NULL
%	NULL
0	NULL
433	NULL
%	NULL
-	NULL
204	NULL
%	NULL
-	NULL
115	NULL
%	NULL
No	NULL
.	NULL

of	NULL
samples	NULL
4	NULL
4	NULL
2	NULL
3	NULL
2	NULL
PH	NULL
]	NULL
-thymidine	NULL
68	NULL
16-0	NULL
31-6	NULL
155	NULL
10-4	NULL
uptake	NULL
with	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
dexamethasone	NULL
23	NULL
131	NULL
250	NULL
11-0	NULL
7-7	NULL
(	NULL
x	NULL
10Â°	NULL
ct/min	NULL
)	NULL
H	NULL
]	NULL
-thymidine	NULL
19-7	NULL
237	NULL
42+5	NULL
257	NULL
16-9	NULL
uptake	NULL
without	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
dexamethasone	NULL
59	NULL
11-4	NULL
15-3	NULL
8-3	NULL
9:9	NULL
(	NULL
x	NULL
10Â°	NULL
ct/min	NULL
'Relative	NULL
'	NULL
32-5	NULL
62-0*	NULL
68-0	NULL
55-8	NULL
58-3	NULL
thymidine	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
uptake	NULL
(	NULL
%	NULL
)	NULL
18-6	NULL
227	NULL
33-9	NULL
21-5	NULL
11-0	NULL
[	NULL
?	NULL

H-thymidine	NULL
-	NULL
2056*	NULL
_	NULL
1624	NULL
129-3	NULL
95-6	NULL
uptake	NULL
compared	NULL
+	NULL
+	NULL
+	NULL
+	NULL
to	NULL
control	NULL
58	NULL
%	NULL
135	NULL
%	NULL
,	NULL
-	NULL
665	NULL
%	NULL
,	NULL
-	NULL
199	NULL
%	NULL
TMS=TMS	NULL
F5	NULL
.	NULL

IL-2=Interleukin-2	NULL
(	NULL
1	NULL
:	NULL
10	NULL
dilution	NULL
)	NULL
.	NULL

*	NULL
P	NULL
<	NULL
0-01	NULL
.	NULL

.	NULL

all	NULL
viable	NULL
cell	NULL
with	NULL
dexamethasone	NULL
Relative	NULL
cell	NULL
viability	NULL
=	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
.	NULL

viable	NULL
cell	NULL
without	NULL
dexamethasone	NULL
See	NULL
text	NULL
for	NULL
further	NULL
explanation	NULL
.	NULL

viability	NULL
to	NULL
33-8	NULL
+9-7	NULL
%	NULL
and	NULL
in	NULL
'	NULL
H-thymidine	NULL
uptake	NULL
to	NULL
32-5	NULL
+	NULL
18:6	NULL
%	NULL
,	NULL
of	NULL
control	NULL
cells	NULL
,	NULL
i.e	NULL
.	NULL

untreated	NULL
with	NULL
dexamethasone	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
thymocytes	NULL
treated	NULL
with	NULL
TMS	NULL
F5	NULL
were	NULL
less	NULL
sensitive	NULL
than	NULL
controls	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
dexamethasone	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Viability	NULL
of	NULL
thymocytes	NULL
treated	NULL
with	NULL
TMS	NULL
F5	NULL
at	NULL
150	NULL
and	NULL
300	NULL
ug/ml	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
were	NULL
increased	NULL
to	NULL
162:6+43-3	NULL
%	NULL
,	NULL
and	NULL
168:6+30-7	NULL
%	NULL
of	NULL
control	NULL
values	NULL
respectively	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
IL-2	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
survival	NULL
of	NULL
thymocytes	NULL
exposed	NULL
to	NULL
dexamethasone	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
control	NULL
.	NULL

Thymic	NULL
derived	NULL
acute	NULL
leukaemia	NULL
cell	NULL
line	NULL
(	NULL
MOLT	NULL
3	NULL
)	NULL
Effect	NULL
of	NULL
TMS	NULL
F5	NULL
on	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

In	NULL
three	NULL
experiments	NULL
,	NULL
MOLT	NULL
3	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
have	NULL
4,510	NULL
+	NULL
2,055	NULL
binding	NULL
sites	NULL
per	NULL
cell	NULL
and	NULL
a	NULL
Kd	NULL
of	NULL
1:7+0-9	NULL
x	NULL
1078	NULL
m.	NULL
After	NULL
4	NULL
days	NULL
incubation	NULL
,	NULL
the	NULL
specific	NULL
dexamethasone	NULL
binding	NULL
activity	NULL
(	NULL
11-1	NULL
+	NULL
1-5	NULL
fmole/m1	NULL
)	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
TMS	NULL
F5	NULL
(	NULL
150	NULL
ug/ml	NULL
)	NULL
was	NULL
442+153	NULL
%	NULL
,	NULL
of	NULL
control	NULL
(	NULL
P	NULL
>	NULL
0-05	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
specific	NULL
dexamethasone	NULL
binding	NULL
278	NULL
D.	NULL
D.	NULL
F.	NULL
Ma	NULL
,	NULL
A.	NULL
H.	NULL
Ho	NULL
&	NULL
A.	NULL
V.	NULL
Hoffbrand	NULL
(	NULL
17-8	NULL
+	NULL
5-8	NULL
fmole/m	NULL
!	NULL

1	NULL
)	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
TPA	NULL
was	NULL
77-9	NULL
+	NULL
18-3	NULL
%	NULL
,	NULL
of	NULL
control	NULL
(	NULL
P	NULL
not	NULL
significant	NULL
)	NULL
.	NULL

The	NULL
control	NULL
value	NULL
was	NULL
23:9	NULL
+9-3	NULL
fmole/ml	NULL
.	NULL

There	NULL
was	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
steroid	NULL
binding	NULL
of	NULL
MOLT	NULL
3	NULL
cells	NULL
treated	NULL
with	NULL
or	NULL
without	NULL
TMS	NULL
for	NULL
24	NULL
h.	NULL
In	NULL
the	NULL
experiments	NULL
with	NULL
RAJI	NULL
cells	NULL
(	NULL
a	NULL
B	NULL
lymphoma	NULL
line	NULL
)	NULL
,	NULL
4	NULL
day	NULL
incubation	NULL
with	NULL
TMS	NULL
FS	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
number	NULL
of	NULL
steroid	NULL
receptors	NULL
.	NULL

Steroid	NULL
receptors	NULL
of	NULL
TMS	NULL
treated	NULL
samples	NULL
were	NULL
46-6	NULL
+	NULL
12-8	NULL
fmole/m1	NULL
,	NULL
and	NULL
of	NULL
controls	NULL
49:0	NULL
+9-0	NULL
fmole/ml	NULL
.	NULL

Effect	NULL
of	NULL
thymosin	NULL
on	NULL
glucocorticoid	NULL
sensitivity	NULL
.	NULL

MOLT	NULL
3	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
be	NULL
relatively	NULL
resistant	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
.	NULL

At	NULL
a	NULL
dexamethasone	NULL
concentration	NULL
of	NULL
2:5	NULL
x	NULL
10-Â®m	NULL
,	NULL
the	NULL
viability	NULL
of	NULL
TMS	NULL
F5	NULL
treated	NULL
and	NULL
untreated	NULL
samples	NULL
,	NULL
were	NULL
similar	NULL
(	NULL
~91-:0+5:2	NULL
%	NULL
,	NULL
and	NULL
92-2	NULL
+	NULL
25	NULL
%	NULL
,	NULL
respectively	NULL
,	NULL
average	NULL
of	NULL
three	NULL
experiments	NULL
)	NULL
.	NULL

Thymosin	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
viability	NULL
nor	NULL
the	NULL
thymidine	NULL
uptake	NULL
of	NULL
RAJIT	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
similar	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
results	NULL
show	NULL
that	NULL
human	NULL
thymocytes	NULL
are	NULL
sensitive	NULL
to	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
.	NULL

The	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
and	NULL
*H-thymidine	NULL
incorporation	NULL
tests	NULL
were	NULL
markedly	NULL
reduced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2:5	NULL
x	NULL
10-Â®m	NULL
dexamethasone	NULL
(	NULL
33-8	NULL
+9-7	NULL
%	NULL
and	NULL
32-5	NULL
+	NULL
18:6	NULL
%	NULL
of	NULL
control	NULL
,	NULL
respectively	NULL
,	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
in	NULL
vitro	NULL
studies	NULL
which	NULL
showed	NULL
that	NULL
human	NULL
thymocytes	NULL
are	NULL
highly	NULL
resistant	NULL
to	NULL
cytolytic	NULL
effects	NULL
of	NULL
steroids	NULL
(	NULL
Claman	NULL
,	NULL
Moorhead	NULL
&	NULL
Benner	NULL
,	NULL
1971	NULL
;	NULL
Galili	NULL
,	NULL
Prokocimer	NULL
&	NULL
Izak	NULL
,	NULL
1980	NULL
)	NULL
.	NULL

Their	NULL
samples	NULL
were	NULL
from	NULL
an	NULL
older	NULL
age	NULL
group	NULL
.	NULL

Age	NULL
related	NULL
changes	NULL
in	NULL
the	NULL
lymphoid	NULL
cells	NULL
of	NULL
the	NULL
thymuses	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
Singh	NULL
&	NULL
Singh	NULL
,	NULL
1979	NULL
)	NULL
.	NULL

The	NULL
present	NULL
results	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
study	NULL
of	NULL
infant	NULL
thymocytes	NULL
by	NULL
Homo	NULL
&	NULL
Duval	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
in	NULL
vivo	NULL
administration	NULL
of	NULL
glucocorticoids	NULL
caused	NULL
profound	NULL
acute	NULL
reduction	NULL
in	NULL
the	NULL
size	NULL
of	NULL
infant	NULL
thymuses	NULL
(	NULL
Caffey	NULL
&	NULL
Silbey	NULL
,	NULL
1960	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
human	NULL
infant	NULL
thymocytes	NULL
was	NULL
found	NULL
to	NULL
be	NULL
2,145	NULL
+725/cell	NULL
with	NULL
a	NULL
Kd	NULL
of	NULL
1-4+0-6	NULL
x	NULL
10-Â®m	NULL
.	NULL

This	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
reported	NULL
for	NULL
humans	NULL
(	NULL
Homo	NULL
&	NULL
Duval	NULL
,	NULL
1979	NULL
)	NULL
and	NULL
is	NULL
half	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites/cell	NULL
found	NULL
in	NULL
murine	NULL
thymocytes	NULL
(	NULL
Wira	NULL
&	NULL
Munck	NULL
,	NULL
1974	NULL
;	NULL
Osheroff	NULL
,	NULL
1981	NULL
)	NULL
.	NULL

The	NULL
receptor	NULL
binding	NULL
of	NULL
thymocytes	NULL
reported	NULL
here	NULL
is	NULL
slightly	NULL
lower	NULL
than	NULL
that	NULL
reported	NULL
for	NULL
normal	NULL
adult	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
by	NULL
Lippman	NULL
&	NULL
Barr	NULL
(	NULL
1977	NULL
)	NULL
.	NULL

Incubation	NULL
with	NULL
TMS	NULL
F5	NULL
reduced	NULL
the	NULL
amount	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
human	NULL
thymocytes	NULL
and	NULL
increased	NULL
their	NULL
resistance	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
dexamethasone	NULL
(	NULL
Tables	NULL
2	NULL
&	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

No	NULL
such	NULL
changes	NULL
were	NULL
detected	NULL
when	NULL
thymocytes	NULL
were	NULL
incubated	NULL
with	NULL
other	NULL
inducing	NULL
agents	NULL
,	NULL
e.g	NULL
.	NULL

IL-2	NULL
,	NULL
TP5	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

TMS	NULL
is	NULL
produced	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

The	NULL
blood	NULL
level	NULL
of	NULL
a	NULL
purified	NULL
TMS	NULL
peptide	NULL
Â«	NULL
;	NULL
in	NULL
humans	NULL
is	NULL
found	NULL
to	NULL
be	NULL
highest	NULL
in	NULL
infant	NULL
and	NULL
decreases	NULL
with	NULL
age	NULL
(	NULL
Goldstein	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

TMS	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
possess	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
action	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

Most	NULL
reports	NULL
are	NULL
on	NULL
pre-	NULL
and	NULL
post-thymic	NULL
rather	NULL
than	NULL
intrathymic	NULL
T	NULL
cells	NULL
(	NULL
reviewed	NULL
by	NULL
Bach	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Goldstein	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
TMS	NULL
peptides	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
induce	NULL
5'-nucleotidase	NULL
activity	NULL
(	NULL
Cohen	NULL
,	NULL
Dosch	NULL
&	NULL
Gelfand	NULL
,	NULL
1981	NULL
)	NULL
and	NULL
changes	NULL
in	NULL
enzyme	NULL
and	NULL
surface	NULL
antigenic	NULL
markers	NULL
of	NULL
human	NULL
thymocytes	NULL
(	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983b	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
another	NULL
physiological	NULL
role	NULL
of	NULL
TMS	NULL
in	NULL
intrathymic	NULL
T	NULL
cell	NULL
differentiation	NULL
in	NULL
man	NULL
was	NULL
demonstrated	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
changes	NULL
in	NULL
receptor	NULL
binding	NULL
and	NULL
glucocorticoid	NULL
sensitivity	NULL
in	NULL
TMS	NULL
treated	NULL
thymocytes	NULL
might	NULL
represent	NULL
two	NULL
or	NULL
more	NULL
independent	NULL
events	NULL
,	NULL
e.g	NULL
.	NULL

changes	NULL
in	NULL
cell	NULL
viability	NULL
or	NULL
in	NULL
cell	NULL
cycle	NULL
or	NULL
differentiation	NULL
changes	NULL
.	NULL

The	NULL
change	NULL
in	NULL
glucocorticoid	NULL
receptors	NULL
by	NULL
TMS	NULL
F5	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
caused	NULL
by	NULL
changes	NULL
in	NULL
the	NULL
cell	NULL
viability	NULL
or	NULL
cell	NULL
cycle	NULL
since	NULL
the	NULL
thymidine	NULL
uptake	NULL
and	NULL
trypan	NULL
blue	NULL
exclusion	NULL
tests	NULL
of	NULL
the	NULL
treated	NULL
cells	NULL
prior	NULL
to	NULL
the	NULL
dexamethasone	NULL
incubation	NULL
were	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
control	NULL
.	NULL

The	NULL
other	NULL
possibility	NULL
that	NULL
TMS	NULL
FS	NULL
induced	NULL
changes	NULL
in	NULL
the	NULL
specific	NULL
glucocorticoid	NULL
binding	NULL
and	NULL
glucocorticoid	NULL
resistance	NULL
of	NULL
different	NULL
subsets	NULL
of	NULL
thymocytes	NULL
is	NULL
unlikely	NULL
but	NULL
can	NULL
not	NULL
definitely	NULL
be	NULL
excluded	NULL
.	NULL

T	NULL
cell	NULL
leukaemias	NULL
are	NULL
thought	NULL
to	NULL
represent	NULL
malignant	NULL
clonal	NULL
expansion	NULL
of	NULL
cells	NULL
arrested	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
normal	NULL
T	NULL
cell	NULL
development	NULL
(	NULL
Greaves	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
;	NULL
Ma	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
.	NULL

It	NULL
is	NULL
thus	NULL
of	NULL
interest	NULL
to	NULL
investigate	NULL
whether	NULL
Thy-ALL	NULL
cells	NULL
behave	NULL
similarly	NULL
to	NULL
their	NULL
normal	NULL
counterparts	NULL
,	NULL
the	NULL
Thymosin	NULL
effect	NULL
on	NULL
human	NULL
thymocytes	NULL
279	NULL
!	NULL

arge	NULL
cortical	NULL
thymic	NULL
blasts	NULL
(	NULL
Bradstock	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
;	NULL
Ma	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
TMS	NULL
F5	NULL
did	NULL
induce	NULL
similar	NULL
glucocorticoid	NULL
receptor	NULL
changes	NULL
in	NULL
the	NULL
Thy-ALL	NULL
cell	NULL
line	NULL
(	NULL
MOLT	NULL
3	NULL
)	NULL
to	NULL
those	NULL
in	NULL
normal	NULL
thymocytes	NULL
and	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
of	NULL
the	NULL
B	NULL
cell	NULL
line	NULL
(	NULL
Raji	NULL
)	NULL
.	NULL

However	NULL
,	NULL
MOLT	NULL
3	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
be	NULL
more	NULL
resistant	NULL
to	NULL
the	NULL
cytolytic	NULL
effect	NULL
of	NULL
dexamethasone	NULL
(	NULL
2:5	NULL
x	NULL
10-Â®m	NULL
)	NULL
than	NULL
normal	NULL
thymocytes	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
correlation	NULL
between	NULL
steroid	NULL
receptor	NULL
activity	NULL
and	NULL
response	NULL
to	NULL
glucocorticoid	NULL
could	NULL
be	NULL
related	NULL
to	NULL
functionally	NULL
abnormal	NULL
steroid	NULL
receptors	NULL
in	NULL
leukaemic	NULL
cells	NULL
as	NULL
demonstrated	NULL
by	NULL
McCaffrey	NULL
,	NULL
Lillquist	NULL
&	NULL
Bell	NULL
(	NULL
1981	NULL
)	NULL
and	NULL
may	NULL
be	NULL
relevant	NULL
to	NULL
developmept	NULL
of	NULL
resistance	NULL
to	NULL
steroid	NULL
therapy	NULL
in	NULL
Thy-ALL	NULL
cases	NULL
.	NULL

TMS	NULL
F5	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
surface	NULL
antigens	NULL
and	NULL
enzyme	NULL
changes	NULL
including	NULL
TdT	NULL
,	NULL
ADA	NULL
and	NULL
SNT	NULL
in	NULL
T	NULL
leukaemic	NULL
cell	NULL
lines	NULL
(	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
Â¥983a	NULL
,	NULL
1983b	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
the	NULL
findings	NULL
reported	NULL
here	NULL
,	NULL
it	NULL
suggests	NULL
that	NULL
thymosin	NULL
peptides	NULL
induce	NULL
Thy-ALL	NULL
cells	NULL
to	NULL
differentiate	NULL
.	NULL

Physiological	NULL
differentiation	NULL
inducing	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
cause	NULL
differentiation	NULL
in	NULL
some	NULL
myeloid	NULL
leukaemic	NULL
cells	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
Sachs	NULL
,	NULL
1982	NULL
;	NULL
Metcalf	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

It	NULL
would	NULL
be	NULL
of	NULL
therapeutic	NULL
interest	NULL
if	NULL
blast	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
Thy-ALL	NULL
â	NULL
could	NULL
â	NULL
also	NULL
be	NULL
induced	NULL
to	NULL
differentiate	NULL
by	NULL
thymosin	NULL
and	NULL
related	NULL
compounds	NULL
.	NULL

The	NULL
.	NULL

authors	NULL
thank-Dr	NULL
W.E	NULL
.	NULL

Scott	NULL
of	NULL
Hoffman	NULL
La	NULL
Roche	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
thymosin	NULL
and	NULL
Mrs	NULL
Megan	NULL
Evans	NULL
for	NULL
typing	NULL
the	NULL
manuscript	NULL
.	NULL

The	NULL
authors	NULL
are	NULL
indebted	NULL
to	NULL
Mr	NULL
Lincoln	NULL
of	NULL
Brompton	NULL
Hospital	NULL
,	NULL
London	NULL
and	NULL
his	NULL
surgical	NULL
team	NULL
,	NULL
particularly	NULL
Mr	NULL
Pillei	NULL
,	NULL
for	NULL
the	NULL
supply	NULL
of	NULL
thymic	NULL
specimens	NULL
.	NULL

D.D.F.M	NULL
.	NULL

is	NULL
supported	NULL
by	NULL
the	NULL
Clothworker	NULL
's	NULL
Foundation	NULL
and	NULL
A.H.H	NULL
.	NULL

by	NULL
the	NULL
Mildred-Steel-Stipendium	NULL
of	NULL
the	NULL
Deutsche	NULL
Knabshilfe	NULL
.	NULL

REFERENCES	NULL
BACH	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
Back	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
CHARREIRE	NULL
,	NULL
J.	NULL
,	NULL
DaRDENNE	NULL
,	NULL
M.	NULL
&	NULL
PrEAaU	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
The	NULL
mode	NULL
of	NULL
action	NULL
of	NULL
thymic	NULL
hormones	NULL
.	NULL

Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

332	NULL
,	NULL
23	NULL
.	NULL

BaxtTEr	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Harris	NULL
,	NULL
A.W	NULL
.	NULL

,	NULL
Tomkins	NULL
,	NULL
G.M	NULL
.	NULL

&	NULL
CoHEn	NULL
,	NULL
M.	NULL
(	NULL
1971	NULL
)	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
lymphoma	NULL
cells	NULL
in	NULL
culture	NULL
:	NULL
relationship	NULL
to	NULL
glucocorticoid	NULL
killing	NULL
activity	NULL
.	NULL

Science	NULL
,	NULL
171	NULL
,	NULL
189	NULL
.	NULL

BrapsTOck	NULL
,	NULL
K.F	NULL
.	NULL

,	NULL
Janossy	NULL
,	NULL
G.	NULL
,	NULL
Pizzoro	NULL
,	NULL
G.	NULL
,	NULL
HorrBRAND	NULL
,	NULL
A.V	NULL
.	NULL

,	NULL
McMiIcHaEL	NULL
,	NULL
A.	NULL
,	NULL
PiccH	NULL
,	NULL
J.R.	NULL
,	NULL
Mi-sTEIN	NULL
,	NULL
C..	NULL
NeverLEv	NULL
,	NULL
P.	NULL
&	NULL
F.J.	NULL
(	NULL
1980	NULL
)	NULL
Subpopulations	NULL
of	NULL
normal	NULL
and	NULL
leukaemia	NULL
human	NULL
lymphocytes	NULL
:	NULL
an	NULL
analysis	NULL
with	NULL
the	NULL
use	NULL
of	NULL
monoc-lonal	NULL
antibodies	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

65	NULL
,	NULL
33	NULL
.	NULL

Carrey	NULL
,	NULL
J	NULL
.	NULL

&	NULL
R.	NULL
(	NULL
1960	NULL
)	NULL
Regrowth	NULL
and	NULL
overgrowth	NULL
of	NULL
the	NULL
thymus	NULL
after	NULL
atrophy	NULL
induced	NULL
by	NULL
the	NULL
oral	NULL
administration	NULL
of	NULL
adrenocorticosteroids	NULL
to	NULL
human	NULL
infants	NULL
.	NULL

Pediatrics	NULL
,	NULL
26	NULL
,	NULL
762	NULL
.	NULL

CiptowskK1	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
MicHaELs	NULL
,	NULL
G.A	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Alteration	NULL
in	NULL
glucocorticoid	NULL
binding	NULL
site	NULL
number	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

Nature	NULL
,	NULL
266	NULL
,	NULL
643	NULL
.	NULL

CLamaAN	NULL
,	NULL
HN	NULL
.	NULL

,	NULL
MoorrEaD	NULL
,	NULL
J.W	NULL
.	NULL

&	NULL
Benner	NULL
,	NULL
W.H	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
in	NULL
rifro	NULL
.	NULL

I.	NULL
Hydrocortisol	NULL
lysis	NULL
of	NULL
human	NULL
,	NULL
guinea	NULL
pig	NULL
,	NULL
and	NULL
mouse	NULL
thymus	NULL
cells	NULL
.	NULL

J.	NULL
Zab	NULL
.	NULL

clin	NULL
.	NULL

Med	NULL
.	NULL

78	NULL
,	NULL
499	NULL
.	NULL

Craman	NULL
,	NULL
HN	NULL
.	NULL

(	NULL
1972	NULL
)	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

287	NULL
,	NULL
388	NULL
.	NULL

CoxEn	NULL
,	NULL
A.	NULL
,	NULL
Doses	NULL
,	NULL
H.-M.	NULL
&	NULL
GELFAND	NULL
,	NULL
E.W	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Induction	NULL
of	NULL
ecto-5'-nucleotidase	NULL
activity	NULL
in	NULL
human	NULL
thymocytes	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

|	NULL
Immunopath	NULL
.	NULL

18	NULL
,	NULL
287	NULL
.	NULL

Gaui	NULL
,	NULL
U.	NULL
,	NULL
ProkocimEeR	NULL
,	NULL
M.	NULL
&	NULL
Izak	NULL
,	NULL
G.	NULL
(	NULL
1980	NULL
)	NULL
The	NULL
in	NULL
vitro	NULL
sensitivity	NULL
of	NULL
leukemic	NULL
and	NULL
normal	NULL
leukocytes	NULL
to	NULL
hydrocortisone	NULL
induced	NULL
cytolysis	NULL
.	NULL

Blood	NULL
,	NULL
56	NULL
,	NULL
1077	NULL
.	NULL

GOLDSTEIN	NULL
,	NULL
AL	NULL
.	NULL

,	NULL
Low	NULL
,	NULL
TLK	NULL
.	NULL

,	NULL
THURMAN	NULL
,	NULL
G.B	NULL
.	NULL

,	NULL
Zaz	NULL
,	NULL
MM	NULL
.	NULL

,	NULL
Haut	NULL
,	NULL
N.	NULL
,	NULL
CHEN	NULL
,	NULL
J.	NULL
,	NULL
Hu	NULL
,	NULL
S.-K.	NULL
,	NULL
Navior	NULL
,	NULL
P.B	NULL
.	NULL

&	NULL
McCuure	NULL
,	NULL
J.E	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Current	NULL
status	NULL
of	NULL
thymosin	NULL
and	NULL
other	NULL
hormones	NULL
of	NULL
the	NULL
thymus	NULL
gland	NULL
.	NULL

Recent	NULL
Prog	NULL
.	NULL

Horm	NULL
.	NULL

Res	NULL
.	NULL

17	NULL
,	NULL
369	NULL
.	NULL

GrEaAvEs	NULL
,	NULL
MF	NULL
.	NULL

,	NULL
Rao	NULL
,	NULL
J.	NULL
,	NULL
Hariri	NULL
,	NULL
G.	NULL
&	NULL
Versi	NULL
,	NULL
W.	NULL
(	NULL
1981	NULL
)	NULL
Phenotypic	NULL
heterogeneity	NULL
and	NULL
cellular	NULL
origins	NULL
of	NULL
T	NULL
cell	NULL
malignancies	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

5	NULL
,	NULL
281	NULL
.	NULL

Harris	NULL
,	NULL
A.W	NULL
.	NULL

&	NULL
Baxter	NULL
,	NULL
J.D	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Variation	NULL
in	NULL
cellular	NULL
sensitivity	NULL
to	NULL
glucocorticoids	NULL
:	NULL
Observations	NULL
and	NULL
Mechanisms	NULL
.	NULL

In	NULL
Glucocorticoid	NULL
Hormone	NULL
Action	NULL
.	NULL

Monographs	NULL
on	NULL
Endocrinology	NULL
,	NULL
Vol	NULL
.	NULL

12	NULL
(	NULL
ed	NULL
.	NULL

J.D	NULL
.	NULL

Baxter	NULL
,	NULL
G.G	NULL
.	NULL

Rousseau	NULL
)	NULL
p.	NULL
424	NULL
.	NULL

Springer	NULL
Verlag	NULL
,	NULL
Berlin	NULL
.	NULL

Hicams	NULL
,	NULL
SJ	NULL
.	NULL

&	NULL
Gexnrinc	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
Molecular	NULL
mechanisms	NULL
of	NULL
steroid	NULL
hormone	NULL
action	NULL
.	NULL

Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

28	NULL
,	NULL
313	NULL
.	NULL

Ho	NULL
,	NULL
A.D.	NULL
,	NULL
Ma	NULL
,	NULL
D.D.F	NULL
.	NULL

,	NULL
Price	NULL
,	NULL
G.	NULL
&	NULL
HOFFBRAND	NULL
,	NULL
A.V	NULL
.	NULL

(	NULL
19832	NULL
)	NULL
Effect	NULL
of	NULL
thymosin	NULL
and	NULL
phorbol	NULL
ester	NULL
on	NULL
purine	NULL
metabolic	NULL
enzymes	NULL
and	NULL
cell	NULL
surface	NULL
phenotype	NULL
in	NULL
a	NULL
malignant	NULL
T-cell	NULL
line	NULL
(	NULL
MOLT-3	NULL
)	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

(	NULL
In	NULL
press	NULL
)	NULL
.	NULL

Ho	NULL
,	NULL
A.p	NULL
.	NULL

,	NULL
Ma	NULL
.	NULL

,	NULL
D.D.F	NULL
.	NULL

,	NULL
PRICE	NULL
,	NULL
G.	NULL
,	NULL
HunstEiN	NULL
,	NULL
W.	NULL
&	NULL
HorrBRAND	NULL
,	NULL
A.V	NULL
.	NULL

(	NULL
1983b	NULL
)	NULL
Biochemical	NULL
and	NULL
im-munological	NULL
differentiation	NULL
of	NULL
human	NULL
thymocytes	NULL
induced	NULL
by	NULL
thymic	NULL
hormones	NULL
.	NULL

Immunology	NULL
,	NULL
(	NULL
In	NULL
press	NULL
)	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
&	NULL
DuvaL	NULL
,	NULL
D.	NULL
(	NULL
1979	NULL
)	NULL
Human	NULL
thymus	NULL
cells	NULL
:	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
clin	NULL
.	NULL

lab	NULL
.	NULL

Immunol	NULL
.	NULL

2	NULL
,	NULL
329	NULL
.	NULL

Horowitz	NULL
,	NULL
S.D	NULL
.	NULL

&	NULL
GoLpsTEIN	NULL
,	NULL
AL	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
The	NULL
in	NULL
vitro	NULL
induction	NULL
of	NULL
differentiation	NULL
of	NULL
putative	NULL
human	NULL
stem	NULL
cells	NULL
by	NULL
thymosin	NULL
and	NULL
agents	NULL
that	NULL
affect	NULL
cyclic	NULL
AMP	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopath	NULL
.	NULL

8	NULL
,	NULL
408	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
&	NULL
Barr	NULL
,	NULL
R.	NULL
(	NULL
1977	NULL
)	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
purified	NULL
subpopulations	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

118	NULL
,	NULL
1977	NULL
.	NULL

Ma	NULL
,	NULL
D.D.F	NULL
.	NULL

,	NULL
SyEwEsTROWICZ	NULL
,	NULL
TA	NULL
.	NULL

,	NULL
Granger	NULL
,	NULL
S..	NULL
280	NULL
Massara	NULL
,	NULL
M.	NULL
,	NULL
Franks	NULL
,	NULL
R.	NULL
,	NULL
Janossy	NULL
,	NULL
G.	NULL
&	NULL
HorrBRAND	NULL
,	NULL
A.V	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Distribution	NULL
of	NULL
terminal	NULL
deox-ynucleotidyl	NULL
transferase	NULL
and	NULL
purine	NULL
degradative	NULL
and	NULL
synthetic	NULL
enzymes	NULL
in	NULL
subpopulations	NULL
of	NULL
human	NULL
thymocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

129	NULL
,	NULL
1430	NULL
.	NULL

Ma	NULL
,	NULL
D.D.F	NULL
.	NULL

,	NULL
Massaia	NULL
,	NULL
M.	NULL
,	NULL
SYLWEsSTROWICZ	NULL
,	NULL
TA	NULL
.	NULL

,	NULL
Price	NULL
,	NULL
G.	NULL
&	NULL
HorrBrRanp	NULL
,	NULL
A.V	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Comparison	NULL
of	NULL
purine	NULL
degradative	NULL
enzymes	NULL
and	NULL
terminal	NULL
deox-ynucleotidyl	NULL
transferase	NULL
in	NULL
T	NULL
cell	NULL
leukaemias	NULL
and	NULL
in	NULL
normal	NULL
thymic	NULL
and	NULL
post-thymic	NULL
T	NULL
cells	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Haematol	NULL
,	NULL
54	NULL
,	NULL
451	NULL
.	NULL

McCarrREey	NULL
,	NULL
R.	NULL
,	NULL
Liriquist	NULL
,	NULL
A	NULL
.	NULL

&	NULL
BELL	NULL
,	NULL
R.	NULL
(	NULL
1981	NULL
)	NULL
Characterization	NULL
of	NULL
the	NULL
forms	NULL
of	NULL
glucocorticoid	NULL
binders	NULL
in	NULL
leukemia	NULL
cytosols	NULL
.	NULL

In	NULL
Leukemia	NULL
Markers	NULL
(	NULL
ed	NULL
.	NULL

W.	NULL
Knapp	NULL
)	NULL
p.	NULL
535	NULL
.	NULL

Academic	NULL
Press	NULL
,	NULL
London	NULL
.	NULL

METcALF	NULL
,	NULL
D.	NULL
(	NULL
1983	NULL
)	NULL
Clonal	NULL
analysis	NULL
of	NULL
the	NULL
response	NULL
of	NULL
HL60	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
to	NULL
biological	NULL
regulators	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

7	NULL
,	NULL
117	NULL
.	NULL

OsHEROFF	NULL
,	NULL
P.L	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
The	NULL
effect	NULL
of	NULL
thymosin	NULL
on	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

60	NULL
,	NULL
376	NULL
.	NULL

D.	NULL
D.	NULL
F.	NULL
Ma	NULL
,	NULL
A.	NULL
H.	NULL
Ho	NULL
&	NULL
A.	NULL
V.	NULL
Hoffbrand	NULL
Rosenau	NULL
,	NULL
W.	NULL
,	NULL
BaxtTER	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Rousseau	NULL
,	NULL
G.G	NULL
.	NULL

&	NULL
ToMKINS	NULL
,	NULL
G.	NULL
M.	NULL
(	NULL
1972	NULL
)	NULL
Mechanism	NULL
of	NULL
resistance	NULL
to	NULL
steroids	NULL
:	NULL
glucocorticoid	NULL
receptor	NULL
defect	NULL
in	NULL
lymphoma	NULL
cells	NULL
.	NULL

Nature	NULL
,	NULL
237	NULL
,	NULL
20	NULL
.	NULL

SacHs	NULL
,	NULL
L.	NULL
(	NULL
1982	NULL
)	NULL
Normal	NULL
development	NULL
programmes	NULL
in	NULL
myeloid	NULL
leukaemia	NULL
:	NULL
regulatory	NULL
proteins	NULL
in	NULL
the	NULL
control	NULL
of	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Cancer	NULL
Surveys	NULL
,	NULL
1	NULL
,	NULL
321	NULL
.	NULL

Sino	NULL
,	NULL
J	NULL
.	NULL

&	NULL
SinoH	NULL
,	NULL
A.K..	NULL
(	NULL
1979	NULL
)	NULL
Age	NULL
related	NULL
changes	NULL
in	NULL
human	NULL
thymus	NULL
.	NULL

C/in	NULL
.	NULL

exp	NULL
.	NULL

Immunol	NULL
.	NULL

37	NULL
,	NULL
507	NULL
.	NULL

Smith	NULL
,	NULL
K.A	NULL
.	NULL

,	NULL
CrastrREE	NULL
,	NULL
G.R	NULL
.	NULL

,	NULL
KennEoy	NULL
,	NULL
SM	NULL
.	NULL

&	NULL
Munck	NULL
,	NULL
A.U	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
glucocorticoid	NULL
sensitivity	NULL
of	NULL
mitogen	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
human	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
,	NULL
267	NULL
,	NULL
523	NULL
.	NULL

Wira	NULL
,	NULL
CR	NULL
.	NULL

&	NULL
Munck	NULL
,	NULL
A.U	NULL
.	NULL

(	NULL
1974	NULL
)	NULL
Glucocorticoid	NULL
receptor	NULL
complexes	NULL
in	NULL
rat	NULL
thymus	NULL
cells	NULL
.	NULL

'Cytoplas-mic	NULL
'	NULL
nuclear	NULL
transformation	NULL
.	NULL

J.	NULL
biol	NULL
.	NULL

Chem	NULL
.	NULL

249	NULL
,	NULL
5328	NULL
.	NULL

